周五的标签扩展将有助于葛兰素史克在呼吸道合胞病毒疫苗竞赛中保持领先地位。Arexvy 于 2023 年 5 月成为业内首个获得 FDA 批准的呼吸道合胞病毒疫苗，比其主要竞争对手辉瑞的 Abrysvo 提前一个月。

作为儿科医生，曾经面对呼吸道合胞病毒（RSV）感染时，总有一种无力感。但今年略有不同，因为药物预防RSV感染已取得阶段性突破。去年国内开展注射的尼塞韦单抗（乐唯初），可有效减少婴幼儿重症RSV感染的发生。01药物预防目前有三种药物预防方式：1、单克隆 ...

The application seeks approval for use in adults aged 18 to 49 who are at increased risk for severe RSV infection. Arexvy is currently approved in the US for adults aged 60 and older, and for ...

US FDA accepts application to review expanded use of GSK's RSV vaccine, Arexvy, for adults 18-49 at increased risk · More than 21 million US adults under the age of 50 have at least one risk ...

Arexvy contains a recombinant RSV glycoprotein F antigen combined with GSK’s proprietary AS01E adjuvant. The vaccine is approved for prevention of lower respiratory tract disease caused by RSV in ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

(Alliance News) - GSK PLC on Monday said it has submitted a US regulatory application for the expanded use of its Arexvy respiratory syncytial virus vaccine. The London-based drug maker said the ...

(RTTNews) - GSK plc (GSK, GSK.L) announced that the FDA has accepted for review an application to extend the indication of Arexvy or respiratory syncytial virus vaccine, adjuvanted to adults aged ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population ...

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...